<?xml version='1.0' encoding='utf-8'?>
<document id="20170280"><sentence text="Comparative renal excretion of VX-702, a novel p38 MAPK inhibitor, and methotrexate in the perfused rat kidney model."><entity charOffset="71-83" id="DDI-PubMed.20170280.s1.e0" text="methotrexate" /></sentence><sentence text="VX-702 is a novel p38 mitogen-activated protein kinase inhibitor being developed to treat rheumatoid arthritis" /><sentence text="" /><sentence text="To characterize the renal excretion profile of VX-702 using the isolated perfused rat kidney (IPRK) model" /><sentence text="" /><sentence text="Studies were performed to assess the dose linearity of VX-702 excretion and to evaluate the effect of inhibitors of organic anion (probenecid) and organic cation (cimetidine) transport systems on VX-702 disposition"><entity charOffset="163-173" id="DDI-PubMed.20170280.s6.e0" text="cimetidine" /></sentence><sentence text=" VX-702 excretion was studied over a range of doses targeting concentrations between 100 and 600 ng/mL" /><sentence text=" VX-702 (600 ng/mL) was also co-perfused with probenecid (1 mM) and cimetidine (2 mM)"><entity charOffset="46-56" id="DDI-PubMed.20170280.s8.e0" text="probenecid" /><entity charOffset="68-78" id="DDI-PubMed.20170280.s8.e1" text="cimetidine" /><pair ddi="false" e1="DDI-PubMed.20170280.s8.e0" e2="DDI-PubMed.20170280.s8.e0" /><pair ddi="false" e1="DDI-PubMed.20170280.s8.e0" e2="DDI-PubMed.20170280.s8.e1" /></sentence><sentence text=" The results were compared to parallel experiments performed with methotrexate (MTX)"><entity charOffset="66-78" id="DDI-PubMed.20170280.s9.e0" text="methotrexate" /><entity charOffset="80-83" id="DDI-PubMed.20170280.s9.e1" text="MTX" /><pair ddi="false" e1="DDI-PubMed.20170280.s9.e0" e2="DDI-PubMed.20170280.s9.e0" /><pair ddi="false" e1="DDI-PubMed.20170280.s9.e0" e2="DDI-PubMed.20170280.s9.e1" /></sentence><sentence text="" /><sentence text="VX-702 excretion was linear over the range of doses studied, and clearance data were consistent with net reabsorption by the kidney" /><sentence text=" Transport inhibition studies indicate that VX-702 is not a substrate for renal organic anion and organic cation transport systems" /><sentence text=" MTX (500 ng/mL) also displayed net reabsorption in the IPRK, but secretory transport was inhibited upon co-administration with probenecid"><entity charOffset="1-4" id="DDI-PubMed.20170280.s13.e0" text="MTX" /><entity charOffset="128-138" id="DDI-PubMed.20170280.s13.e1" text="probenecid" /><pair ddi="false" e1="DDI-PubMed.20170280.s13.e0" e2="DDI-PubMed.20170280.s13.e0" /><pair ddi="false" e1="DDI-PubMed.20170280.s13.e0" e2="DDI-PubMed.20170280.s13.e1" /></sentence><sentence text=" This finding is consistent with previous IPRK studies that demonstrated inhibitory effects of NSAIDS on MTX excretion"><entity charOffset="105-114" id="DDI-PubMed.20170280.s14.e0" text="MTX" /></sentence><sentence text="" /><sentence text="Overall, this study suggests that a renal drug-drug interaction between VX-702 and MTX would be unlikely if these medications were co-administered"><entity charOffset="83-85" id="DDI-PubMed.20170280.s16.e0" text="MTX" /></sentence><sentence text="" /></document>